Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...

Thank you for joining us for Eli ... Lilly's chair and CEO; Dr. Dan Skovronsky, chief scientific officer and president of Lilly Immunology; Lucas Montarce, chief financial officer; Anne White ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of ...

Eli Lilly has been unable to secure ... and it remains to be seen if either drug will hit the mark in phase 3. Lilly's head of neuroscience R&D Anne White said the company is confident that ...

New investors in the round included Nextech Invest, T Rowe Price Associates, Janus Henderson Investors, RA Capital Management, OrbiMed, Surveyor Capital, Medicxi, Logos Capital, Octagon Capital ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...